# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0000886163-25-000003
Filing Date
2025-02-25
Accepted
2025-02-25 16:02:36
Documents
16
Period of Report
2025-02-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | lgnd-20250224.htm iXBRL | 8-K | 33218
2 | EX-99.1 | exhibit991_castlecreekdeal.htm | EX-99.1 | 18066
6 |  | image_0.jpg | GRAPHIC | 80691
7 |  | image_1.jpg | GRAPHIC | 732944
| Complete submission text file | 0000886163-25-000003.txt |  | 1301399

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
3 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | lgnd-20250224.xsd | EX-101.SCH | 1792
4 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | lgnd-20250224_lab.xml | EX-101.LAB | 22783
5 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | lgnd-20250224_pre.xml | EX-101.PRE | 13053
18 | EXTRACTED XBRL INSTANCE DOCUMENT | lgnd-20250224_htm.xml | XML | 2728

Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 25662916
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)